FDA approves new type of non-opioid pain medication in two decades
FDA approves new type of non-opioid pain medication in two decades - The new drug will be many times more expensive than a ...
Vertex Pharmaceuticals CEO on non-opioid painkiller: It's safe, effective and non-addictive
CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the ...
Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
STAT57m
Pharmalittle: We’re reading about FDA OK for Vertex non-opioid pain drug, vaccine advisory committee, and more
Vertex Pharmaceuticals won approval from the U.S. Food and Drug Administration for a non-opioid pain drug, clearing the way for the rollout of a product that has simultaneously sparked high hopes and ...
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
FDA approves new medication as alternative to opioids for pain treatment
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
New FDA approved "non-opioid" painkiller
A Nigerian man has been extradited to the US to face charges in the “sextortion” of a South Carolina teen who died by suicide in 2022. Prosecutors allege the scammer posed as a young woman, persuaded ...
ConsumerAffairs1h
A new non-opioid pain medication wins Food and Drug Administration approval
The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioi ...
BioSpace1h
Axsome’s Migraine Medicine Clears FDA Bar
The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
WISH-TV2h
Barnes and Noble credits growth to emergence of ‘BookTok’
Discover the latest trends in the business world, from Barnes and Noble's growth fueled by BookTok to the FDA's approval of a new nonopioid pain medication.